^
    Back
    Association details:
    Biomarker:miR-21 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Chemother Pharmacol
    Title:

    Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab

    Published date:
    09/04/2019
    Excerpt:
    These results showed that changes in ser-miR-21 levels were significantly related to NCCT clinical response and prognosis.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1007/s00280-019-03937-9
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Oncotarget
    Title:

    MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

    Excerpt:
    CONTRADICTING EVIDENCE: Overexpression of miR-21 is associated with resistance to neoadjuvant trastuzumab-chemotherapy in HER2-positive breast cancer patients.
    Secondary therapy:
    paclitaxel + doxorubicin hydrochloride
    DOI:
    10.18632/oncotarget.5495